Catalent, Inc. (NYSE:CTLT ) Q4 2023 Earnings Conference Call August 29, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations John Greisch - Executive Chair, Board A...

Catalent (CTLT) records lower revenues in Biologics segment in its fourth-quarter fiscal 2023, resulting in overall soft preliminary performance.

Catalent (CTLT) shares surged more than 5% in early trading on Tuesday after the struggling drugmaker secured a deal with activist investor Elliott Investment Management.

Catalent Inc is close to a settlement deal with activist investor Elliott Investment Management, which will include the appointment new directors and a pledge to review strategic alternatives such ...

Catalent (NYSE: CTLT ) stock is getting a boost on Tuesday after the consumer health company reached an agreement with Elliott Investment Management. This has Catalent adding four new directors to ...

Catalent (CTLT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to earnings of $1.19 per share a year ago.

Shares of Catalent Inc. CTLT, +1.67% jumped 4.1% in premarket trading Tuesday, after the maker of products used by drug makers and consumer health companies announced an cooperation agreement with ...

Catalent Inc is close to reaching a settlement with Elliott Investment Management that would lead to a shake-up of the U.S. contract drug manufacturer's board of directors after its share price los...

Catalent's plant in Bloomington, Indiana, will fill injection pens for Novo Nordisk's weight-loss drug Wegovy as part of the two companies' expanded supply agreement, two sources familiar with the ...

SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release fin...